BATS · NVOH
Healthcare · Medical - Pharmaceuticals
$23.74
Down-$0.61 (-2.58%)
Updated Nov 5, 2026, 10:14 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NVOH
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
NVOH closed at $23.74 after 21 trading sessions, up 10.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $23.93 | $24.08 | $23.7435 | $23.7435 | 1.24K |
| Nov 3, 2026 | $22.70 | $22.70 | $22.6374 | $22.6374 | 444 |
| Nov 2, 2026 | $22.815 | $22.815 | $22.7876 | $22.7876 | 634.61 |
| Oct 30, 2026 | $22.40 | $22.61 | $22.40 | $22.566 | 1.21K |
| Oct 29, 2026 | $21.98 | $22.1603 | $21.98 | $22.1603 | 432 |
| Oct 28, 2026 | $21.85 | $21.85 | $21.61 | $21.6793 | 2.18K |
| Oct 27, 2026 | $22.03 | $22.03 | $21.945 | $21.9556 | 887 |
| Oct 26, 2026 | $22.13 | $22.13 | $22.00 | $22.07 | 557.47 |
| Oct 23, 2026 | $22.01 | $22.0208 | $22.005 | $22.0208 | 526 |
| Oct 22, 2026 | $21.50 | $22.36 | $21.50 | $22.2294 | 1.18K |
| Oct 21, 2026 | $22.10 | $22.10 | $21.9902 | $21.9902 | 791 |
| Oct 20, 2026 | $21.95 | $22.0976 | $21.95 | $22.0976 | 1.26K |
| Oct 19, 2026 | $21.80 | $21.80 | $21.6682 | $21.6682 | 567.42 |
| Oct 16, 2026 | $22.05 | $22.05 | $21.80 | $21.8008 | 518.26 |
| Oct 15, 2026 | $21.66 | $22.275 | $21.66 | $22.0837 | 1.9K |
| Oct 14, 2026 | $21.70 | $21.73 | $21.6238 | $21.6238 | 1.2K |
| Oct 13, 2026 | $21.76 | $21.76 | $21.5272 | $21.5272 | 427.27 |
| Oct 12, 2026 | $20.91 | $21.725 | $20.91 | $21.725 | 384 |
| Oct 9, 2026 | $21.7869 | $21.7869 | $21.7869 | $21.7869 | 65.08 |
| Oct 8, 2026 | $21.03 | $21.67 | $20.60 | $21.67 | 6K |
| Oct 7, 2026 | $19.97 | $21.62 | $19.97 | $21.5775 | 2.94K |
The latest Smart Investors Daily articles mentioning NVOH.
Company
Market Activity
Research & News
NVOH research
Company profile and research snapshot.
The series, under normal circumstances, invests at least 95% of its net assets in American Depositary Receipts (“ADRs”) of the Novo Nordisk A/S (B Shares) (the “Company”). The series will not invest directly in the company. The fund is non-diversified.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
The Motley Fool · Feb 26, 2025
Viking Therapeutics (VKTX) is a biotech company developing a weight loss drug candidate that has shown promising results in clinical trials. The company aims to launch a phase 3 trial for the injectable version of VK2735 in the second quarter. Despite recent stock declines, the article suggests that Viking could be a good buy considering the high-growth weight loss drug market opportunity and the company's progress.
The Motley Fool · Feb 6, 2025
The article discusses Disney's (DIS) first-quarter earnings report, providing an overview of the company's performance and financial results.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NVOH.
No results
No recent SID articles mention NVOH.
